Amylyx Pharmaceuticals, Inc.
AMLX
$32.40
-$1.48-4.37%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 18.93% | 31.41% | 52.03% | 42.47% | -13.10% |
| Total Depreciation and Amortization | -45.58% | -37.32% | -41.92% | -44.78% | -39.79% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -52.56% | -60.22% | -87.74% | -87.76% | -60.70% |
| Change in Net Operating Assets | 93.76% | 105.18% | 97.64% | -58.66% | 10.95% |
| Cash from Operations | 23.59% | 41.83% | 26.43% | -62.43% | -182.26% |
| Capital Expenditure | 99.61% | 99.65% | 99.62% | -7,258.01% | -4,069.39% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -165.93% | 39.43% | -87.34% | 167.44% | 204.31% |
| Cash from Investing | -194.83% | 201.39% | -81.44% | 56.81% | 172.10% |
| Total Debt Issued | 190.86% | 190.86% | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 623.80% | 519.93% | 91.23% | 65.12% | -40.47% |
| Repurchase of Common Stock | -373.83% | -374.00% | -88.40% | -71.23% | 7.11% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 197.92% | 195.37% | 73,758.91% | 54,888.68% | 5,054.35% |
| Foreign Exchange rate Adjustments | -82.56% | 684.73% | 345.21% | 33.02% | 1,221.74% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 43.00% | 253.47% | 261.59% | 343.84% | 90.63% |